Payment overview · 2025
General Payments
$268.60
13 reported records · 9 companies
Healthcare provider profile · identity verified
John Fitzpatrick, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW CITY, NY · NPI 1952472813
Verified facts
What the public records show
CMS Open Payments records show John Fitzpatrick, MD received $268.60 in general payments during 2025 across 13 reported records.
GlaxoSmithKline, LLC. accounted for 18.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.86 | 18.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.19 | 16.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.48 | 13.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.26 | 12.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $31.81 | 11.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.88 | 7.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.77 | 7.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.58 | 5.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.77 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $268.60 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $33.26 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.01 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31.81 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.71 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.71 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 110 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
110 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | 18 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
115 | 42 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1084 | 327 |
| Amlodipine Besylate | Amlodipine Besylate | 954 | 277 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 545 | 174 |
| Metoprolol Succinate | Metoprolol Succinate | 501 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 497 | 151 |
| Losartan Potassium | Losartan Potassium | 399 | 122 |
| Zolpidem Tartrate | Zolpidem Tartrate | 370 | 62 |
| Alprazolam | Alprazolam | 345 | 94 |
| Simvastatin | Simvastatin | 334 | 98 |
| Metformin Hcl | Metformin Hcl | 308 | 85 |
| Meloxicam | Meloxicam | 294 | 104 |
| Pantoprazole Sodium | Pantoprazole Sodium | 294 | 108 |
| Montelukast Sodium | Montelukast Sodium | 290 | 112 |
| Omeprazole | Omeprazole | 290 | 83 |
| Lisinopril | Lisinopril | 212 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 196 | 50 |
| Allopurinol | Allopurinol | 192 | 54 |
| Clonazepam | Clonazepam | 186 | 61 |
| Trazodone Hcl | Trazodone Hcl | 184 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 177 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 54 |
| Gabapentin | Gabapentin | 156 | 56 |
| Valsartan | Valsartan | 154 | 47 |
| Furosemide | Furosemide | 149 | 48 |
| Oxycodone Hcl | Oxycodone Hcl | 149 | 15 |
| Sertraline Hcl | Sertraline Hcl | 149 | 41 |
| Azelastine Hcl | Azelastine Hcl | 141 | 60 |
| Glimepiride | Glimepiride | 128 | 44 |
| Irbesartan | Irbesartan | 126 | 43 |
| Tramadol Hcl | Tramadol Hcl | 123 | 33 |
| Methylprednisolone | Methylprednisolone | 122 | 98 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 39 |
| Cefuroxime | Cefuroxime Axetil | 118 | 94 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 40 |
| Eliquis | Apixaban | 115 | 42 |
| Ezetimibe | Ezetimibe | 114 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 33 |
| Azithromycin | Azithromycin | 110 | 85 |
| Synthroid | Levothyroxine Sodium | 110 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 110 | 42 |
| Famotidine | Famotidine | 107 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 107 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 105 | 86 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 102 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 93 | 30 |
| Bupropion Xl | Bupropion Hcl | 91 | 23 |
| Diazepam | Diazepam | 90 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 24 |
| Atenolol | Atenolol | 82 | 25 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 79 | 24 |
| Finasteride | Finasteride | 79 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 21 |
| Naproxen | Naproxen | 76 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 69 | 19 |
| Donepezil Hcl | Donepezil Hcl | 69 | 24 |
| Lorazepam | Lorazepam | 68 | 16 |
| Meclizine Hcl | Meclizine Hcl | 68 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 68 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 18 |
| Fenofibrate | Fenofibrate | 67 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 66 | 47 |
| Potassium Chloride | Potassium Chloride | 65 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 21 |
| Spironolactone | Spironolactone | 64 | 16 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 63 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 29 |
| Metformin Hcl Er | Metformin Hcl | 58 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 14 |
| Carvedilol | Carvedilol | 50 | 18 |
| Prednisone | Prednisone | 49 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 47 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 45 | 14 |
| Farxiga | Dapagliflozin Propanediol | 45 | 18 |
| Eszopiclone | Eszopiclone | 42 | suppressed |
| Levetiracetam | Levetiracetam | 42 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | suppressed |
| Clotrimazole | Clotrimazole | 41 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Jardiance | Empagliflozin | 40 | suppressed |
| Mupirocin | Mupirocin | 40 | 33 |
| Ramipril | Ramipril | 40 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 19 |
| Clonidine Hcl | Clonidine Hcl | 38 | 12 |
| Labetalol Hcl | Labetalol Hcl | 37 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | 11 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 14 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 30 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 33 | suppressed |
| Cefadroxil | Cefadroxil | 33 | 16 |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 32 | 18 |
| Clobetasol Propionate | Clobetasol Propionate | 31 | 13 |
| Ozempic | Semaglutide | 30 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 24 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | 12 |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 14 |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 12 |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Clarithromycin | Clarithromycin | 15 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Thiothixene | Thiothixene | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $268.60 · 13 records | GlaxoSmithKline, LLC. | BREZTRI, CAMZYOS, CAPLYTA, Cologuard Collection Kit, KISUNLA, MOUNJARO, SHINGRIX, SYNTHROID, TRELEGY ELLIPTA, VOQUEZNA, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error